Basic Daxas Information

• INN (International Nonproprietary Name): Metformin.
• Brand Names Available In United Kingdom: UK/Europe brands listed for the product include Glucophage, Siofor and Metforal.
• ATC Code: A10BA02.
• Forms & Dosages: Immediate‑release tablets (250mg, 500mg, 850mg, 1000mg), extended‑release tablets (500mg, 750mg, 1000mg) and oral solution (500mg/5mL) are specified.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Not specified.
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries.

Critical Warnings & Restrictions (Patient Protection — UK Focus)

Who should be most worried before starting daxas?

Severe hepatic impairment is an absolute contraindication and patients with known severe liver disease must not take daxas.

Patients with a history of depression, suicidal ideation or other significant psychiatric illness need careful assessment before treatment and close follow‑up thereafter.

Marked low body weight or recent unexplained weight loss raises risk of intolerance and requires specialist review.

Pregnancy and breastfeeding are situations where daxas should be avoided unless a COPD specialist advises otherwise because safety data are limited.

Children under 18 years are generally not indicated for daxas and use is not recommended for this age group.

Urgent action checklist — stop the drug and contact your GP or A&E if any of the following red flags appear.

• New or worsening suicidal thoughts or behaviours.
• Rapid, unexplained weight loss.
• Severe, persistent diarrhoea or persistent vomiting.
• Jaundice, dark urine, pale stools, or severe abdominal pain suggesting liver injury.
• Any signs of liver failure such as confusion, easy bruising or bleeding.

Regulatory note: Daxas (roflumilast 500 micrograms) is a Prescription Only Medicine (POM) in the United Kingdom.

The product is MHRA‑approved for selected COPD patients but carries prominent warnings about psychiatric events and clinically relevant weight loss.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Elderly patients should start daxas with caution and require monitoring of weight, mood and liver function during treatment.

Severe hepatic impairment in older patients remains a contraindication.

Pregnancy and breastfeeding: avoid daxas unless an expert pulmonologist or obstetrician gives explicit, documented advice.

Patients with significant chronic illnesses (eg severe heart failure, unstable psychiatric disease) need multidisciplinary assessment before initiation.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Caution is required if dizziness, insomnia or cognitive and psychiatric side effects occur while taking daxas.

UK driving law requires that you are fit to drive and not impaired by medication, so do not drive if attention, coordination or judgement are affected.

Inform occupational health or your employer if you are in a safety‑sensitive role and experience relevant side effects.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: not if you experience dizziness, confusion, visual disturbance, severe fatigue or new psychiatric symptoms.

Stop driving and seek GP or pharmacist advice if any such symptoms develop.

If a medication affects your ability to drive you must inform the DVLA as required by UK regulations.

Usage Basics

INN And Brand Names Available In The UK

The International Nonproprietary Name (INN) for the COPD tablet discussed in this article is roflumilast.

The common UK brand is Daxas, supplied as film‑coated tablets of 500 micrograms for once‑daily dosing.

Legal Classification (POM, P, GSL)

Daxas is classified as a Prescription Only Medicine (POM) in the UK and must normally be dispensed on an NHS or private prescription.

Dispensing requires a valid prescription and appropriate pharmacy checks before supply.

Roflumilast versus other COPD drugs — quick definition list:

• Roflumilast: an oral PDE4 inhibitor for inflammation control and reduction of exacerbations in a chronic bronchitis COPD phenotype.
• Bronchodilators (LABA/LAMA): inhaled agents providing immediate bronchodilation and symptomatic relief.
• Inhaled corticosteroids (ICS): used for exacerbation risk reduction in specific phenotypes, usually combined with bronchodilators.

Pharmacy practicalities: counselling on supply is expected at collection from high‑street chains such as Boots and LloydsPharmacy and via the NHS Electronic Prescription Service (EPS).

Online pharmacies must verify prescription authenticity and patient identity before supplying Daxas tablets.

Cross‑reference: metformin (INN Metformin; ATC A10BA02) belongs to a different therapeutic area and requires different monitoring such as renal function checks and awareness of lactic acidosis risks.

Dosing Guide (NHS Guidance)

Standard Regimen

Typical adult dose for roflumilast (Daxas) is 500 micrograms taken orally once daily, one film‑coated tablet.

Take at approximately the same time each day and the tablet may be taken with or without food.

Adjustments For Comorbidities

Severe hepatic impairment is a contraindication to roflumilast and it must not be used in such patients.

No routine renal dose adjustment is required, but frail and elderly patients should be monitored closely for adverse effects.

Patients with low body weight (under about 50 kg) or those with significant weight loss should be reassessed and may need treatment stopped if further weight loss occurs.

Q&A — “What If I Miss A Dose?”

If you remember the missed dose on the same day, take a single dose then and resume the usual schedule the next day.

If it is almost time for the next dose, skip the missed dose and do not double the dose to catch up.

If vomiting occurs after taking a dose, contact your GP for advice because absorption may have been affected.

Titration checklist and monitoring timetable:

• Baseline weight, mood assessment and liver function tests (LFTs) before starting.
• Weight and mood checks at 4–6 weeks and periodically thereafter.
• Repeat LFTs around three months after initiation or sooner if clinically indicated.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol can worsen psychiatric side effects and appetite loss while taking daxas, so minimising alcohol is advised.

No major direct food interactions are identified, but good nutrition counselling is important because appetite suppression and weight loss can occur.

Caffeine from tea or coffee may aggravate insomnia or anxiety in susceptible patients and should be moderated.

Common Drug Conflicts (MHRA Yellow Card Relevance)

Strong CYP3A4 inhibitors (for example ketoconazole) and CYP1A2 inhibitors (for example fluvoxamine) can raise roflumilast exposure and increase adverse effects.

Strong CYP inducers such as rifampicin, carbamazepine, phenytoin or St John’s wort may reduce roflumilast efficacy by lowering plasma levels.

Co‑prescribing other medicines that cause weight loss or psychiatric adverse events requires close monitoring and consideration of alternative treatments.

Immediate interaction actions — bullet list:

• Avoid or review co‑treatment with strong CYP3A4/CYP1A2 inhibitors; consider specialist advice.
• Avoid co‑treatment with strong CYP inducers where possible.
• Monitor mood and weight closely when starting any new interacting medicine.

Safety reporting: report any suspected adverse reactions to the MHRA Yellow Card scheme promptly.

User Reports & Trends (NHS/Patient‑Info/Mumsnet Insight)

What do patients commonly notice when they start daxas?

Forum summaries and NHS‑facing patient sites commonly report initial gastrointestinal upset such as nausea and diarrhoea.

Patients also frequently report reduced appetite and weight loss, plus sleep disturbance including insomnia early in treatment.

Mood changes, ranging from low mood to anxiety and rarely more serious psychiatric events, are repeatedly mentioned in patient‑reported data.

Many patients who tolerate the medicine long‑term report fewer COPD exacerbations and reduced need for steroids or antibiotics over time.

Thematic patient insights:

• Gastrointestinal upset on initiation.
• Appetite loss and weight loss over the first weeks.
• Mood disturbances and increased anxiety in a minority.
• Sleep disruption, especially insomnia.
• Perceived reduction in exacerbation frequency by long‑term users.

Prescribing trend: roflumilast is used as an add‑on for patients with severe COPD and chronic bronchitis phenotype who continue to have frequent exacerbations despite optimised inhaled therapy.

Pharmacist practical tip: document counselling and plan follow‑up for adverse effects on the patient medication record at supply.

Access & Purchase Options (UK)

High‑Street Chains And Community Pharmacies

Major high‑street dispensers such as Boots, LloydsPharmacy and Superdrug Dispensing supply daxas on presentation of a valid prescription.

Collection steps: present the prescription, show ID where requested, receive counselling and a patient information leaflet from the pharmacist.

Online Pharmacies And NHS E‑Prescriptions

The NHS Electronic Prescription Service (EPS) lets a GP issue a prescription directly to a nominated pharmacy for collection or dispensing.

Online pharmacies will only supply Daxas on a validated prescription and will complete safe‑supply checks before dispatch.

In our online pharmacy, daxas is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Cost And Regional Access

England: standard NHS prescription charges apply unless the patient is exempt.

Scotland, Wales and Northern Ireland: prescriptions are generally free under NHS arrangements in those nations.

Private prescriptions incur a dispensing fee plus the cost of the medicine and vary by supplier; always check the current price with the pharmacy.

Mechanism & Pharmacology

Simplified Explanation

Roflumilast is a selective phosphodiesterase‑4 (PDE4) inhibitor that reduces inflammation in the airways by increasing intracellular cyclic AMP.

Raising cyclic AMP reduces the activity of inflammatory cells and mediators and thereby lowers COPD exacerbation risk in selected patients.

Clinical Terms And Metabolism

Roflumilast is metabolised by hepatic CYP enzymes to an active N‑oxide metabolite, so strong CYP inhibitors and inducers alter exposure.

CYP‑mediated interactions can therefore increase adverse effects or reduce efficacy depending on co‑medication.

Cross‑reference with metformin (INN Metformin, ATC A10BA02):

• PDE4 inhibitors like roflumilast target airway inflammation and require liver monitoring.
• Biguanides like metformin target glucose metabolism and require renal monitoring to reduce lactic acidosis risk.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Daxas (roflumilast) is licensed in the UK as add‑on therapy to reduce the risk of exacerbations in adults with severe COPD associated with chronic bronchitis and frequent exacerbations despite bronchodilator therapy.

Off‑Label Practices In NHS And Private Care

Off‑label use is limited and specialist centres may consider roflumilast in complex overlapping COPD/asthma phenotypes after multidisciplinary team review.

Primary prevention or routine off‑label prescribing is not recommended without documented justification.

Ideal patient phenotype checklist:

• Severe airflow limitation with chronic productive cough.
• Frequent exacerbations despite optimised inhaled bronchodilator and steroid therapy.
• Acceptable liver function and no significant psychiatric history.

Always document MDT justification and provide written information to the patient for any off‑label use.

Key Clinical Findings (UK/EU Evidence Summary 2022–2025)

Clinical trials and pooled analyses show that roflumilast reduces rates of moderate‑to‑severe COPD exacerbations in selected chronic bronchitis patients.

The magnitude of benefit depends on baseline exacerbation risk and trial population and is expressed as relative reduction with varying NNTs in the literature.

Safety signals consistently include weight loss, gastrointestinal effects, sleep disturbance and psychiatric events including depression and rare suicidality.

Hepatic enzyme elevations have been observed occasionally and warrant monitoring.

Clinical practice implication: roflumilast is favourable only for carefully selected patients with documented exacerbations despite optimised inhaled therapy and requires baseline LFTs and a mental‑health screen.

Alternatives Matrix

NHS Prescribing Alternatives

Primary alternatives include optimised inhaled therapy such as LABA, LAMA and ICS combinations tailored to phenotype and exacerbation history.

Other options for select patients include long‑term macrolide therapy, mucolytics and pulmonary rehabilitation to reduce exacerbation risk.

Pros And Cons Checklist

Roflumilast pros: oral once‑daily dosing and evidence for reduced exacerbations in chronic bronchitis phenotype.

Cons: psychiatric risk, weight loss and requirement for hepatic monitoring; it is not a bronchodilator and effects are not immediate.

Clinician decision checklist: assess phenotype suitability, screen for psychiatric history, baseline LFTs, and an agreed monitoring plan with the patient.

Common Questions (UK Patient Consultations)

Can I take Daxas with my inhalers?

Yes, roflumilast is an add‑on therapy and should be continued alongside prescribed inhaled bronchodilators and inhaled corticosteroids.

Will it cause weight loss?

Some patients experience weight loss; significant weight loss should be reported and a dietitian referral considered if needed.

What baseline checks are needed before starting?

Baseline liver function tests, a clinical mental‑health screen, weight measurement and a medication review for potential CYP interactions are recommended.

Can I stop if I feel worse?

Contact your prescriber immediately; for severe psychiatric symptoms or rapid weight loss stop the medicine and seek urgent review.

Quick patient handout points:

• Keep baseline LFTs and mood check appointments.
• Report severe diarrhoea, rapid weight loss or suicidal thoughts immediately.
• For urgent advice out of hours contact NHS 111 or attend A&E for severe symptoms.

NHS Cost & Access Comparison Table

Regional prescription charging summary: Scotland, Wales and Northern Ireland generally provide free prescriptions under NHS arrangements while England applies a standard prescription charge unless the patient is exempt.

When sourcing online, always verify the MHRA‑approved product name (Daxas), prescription authenticity and that the supplying pharmacy is registered with the General Pharmaceutical Council (GPhC).

Registration & Regulation

MHRA Approval Process

Daxas was approved following review of efficacy and safety and remains subject to ongoing pharmacovigilance and periodic safety update reports to the MHRA.

NHS Prescribing Framework

Daxas is POM and local formularies may restrict initial prescribing to secondary care or specialist initiation, with shared‑care agreements varying by trust and ICS.

Formulary submission checklist:

• Provide an evidence summary demonstrating benefit in the target phenotype.
• Provide a cost‑benefit overview and monitoring resource plan.
• Document local governance and shared‑care responsibilities.

Reporting: report new or serious suspected adverse reactions via the Yellow Card scheme and escalate serious psychiatric events through local governance channels.

Storage & Handling (UK Household & Pharmacy)

UK Household Storage (Cold/Damp Climate)

Store Daxas tablets at room temperature below 25°C in a dry place away from humid areas like bathrooms.

Keep the medicine in its original packaging to protect from moisture and light and avoid places near windows or radiators.

Guidance From NHS And Pharmacists

Pharmacists should give printed storage advice and explain safe disposal options, including returning unused tablets to a pharmacy‑managed medicines take‑back point.

Advise patients to keep medicines out of reach of children and to transport tablets in their original box to preserve labelling.

Transport and disposal checklist:

• Carry in the original packaging when travelling.
• Avoid leaving tablets in hot cars or in direct sunlight.
• Return unused tablets to a pharmacy for safe disposal.

Guidelines For Proper Use (Pharmacist Counselling & NHS Safety)

UK Pharmacist Counselling Style

Conduct a brief mental‑health screen and baseline weight measurement before supply and discuss expected benefits and common side effects.

Advise on alcohol moderation, potential interactions and when to seek urgent care for psychiatric or hepatic symptoms.

NHS Patient Safety Advice

Baseline LFTs and mental‑health checks are recommended, with follow‑up LFTs around three months and regular weight and mood monitoring thereafter.

Document counselling on the Electronic Prescription Service record or the patient medication record and arrange follow‑up contact within a few weeks of initiation.

Checklist at point of supply:

• Confirm indication and review current inhaled therapy.
• Record baseline LFTs, weight and mood screen.
• Provide a patient information leaflet and arrange follow‑up review.

Cross‑class awareness: metformin (INN Metformin, ATC A10BA02) requires renal monitoring and has different contraindications and monitoring responsibilities compared with roflumilast.

Delivery Across United Kingdom